Clinical Study to Evaluate the Pharmacokinetic Characteristics Between TMX-67 and Feburic® in Healthy Volunteers
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study was designed to compare and evaluate the pharmacokinetic characteristics of febuxostat after single oral administration of TMX-67 (test drug) and Feburic® tablet in healthy adults; and to evaluate safety and tolerance following a single-dose administration.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
20 Years to 45 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Healthy adult males aged between 20 and 45 years
Subjects whose weight is 50 kg or more and BMI is between 18 and 29 kg/m2
Subjects who were voluntarily decided to participate in the study and provided written informed consent to observe the directions
Medical history which may influence adsorption, distribution, metabolism, excretion of the drug
Clinically significant active chronic disease(s)
Persons who are deemed ineligible for the study by the investigator according to the clinical laboratory test results or for other reasons